Ofatumumab and Complement Replacement in Relapsed/Refractory Chronic Lymphocytic Leukemia.

ABSTRACT:

Background

While many humanized monoclonal antibodies utilize complement-dependent cytotoxicity, the complement depleting effects of these antibodies and the impact of complement replacement on treatment response are not well-described.

Methods

We conducted a phase 2 trial involving patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Patients were treated with ofatumumab with fresh frozen plasma (FFP) used as a source of complement replacement. The primary endpoint was objective response rate. Correlative endpoints included complement levels (C3 and C4) and complement activity (CH50) which was drawn at baseline and after ofatumumab with FFP administration.

Results

Among 12 enrolled patients, overall response rate was 83% with two patients (17%) achie

SUBMITTER: Tuscano J 

PROVIDER: S-EPMC7430864 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature